Holen Sie sich die Stockscreener-App
93.92
0.93%
0.87
Handel nachbörslich:
94.00
0.08
+0.09%
Schlusskurs vom Vortag:
$93.05
Offen:
$93.29
24-Stunden-Volumen:
545.34K
Relative Volume:
0.58
Marktkapitalisierung:
$23.75B
Einnahmen:
$3.26B
Nettoeinkommen (Verlust:
$-1.45B
KGV:
-16.00
EPS:
-5.871
Netto-Cashflow:
$1.18B
1W Leistung:
+4.11%
1M Leistung:
+2.42%
6M Leistung:
-1.34%
1J Leistung:
-12.64%
1-Tages-Spanne:
$92.56
$94.00
1-Wochen-Bereich:
$88.83
$95.08
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
93.92 | 23.53B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates - Traders Union
BioNTech stock trades down as founders leave the company, raising transition concerns - Traders Union
Comirnaty Omicron-adapted formulation from BioNTech SEupdated mRNA shot for the 2024-25 season - AD HOC NEWS
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX) - TradingView
Price to sales forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Oncology Transformation Hinges on Dense Second-Half Data Flow () - aktiencheck.de
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Ubiquiti Upgraded, Reddit Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BioNTech's €16.8 Billion Cash Hoard Is the Prize as Moderna Circles Factories and Spin-Off Looms - aktiencheck.de
Why BioNTech’s BNT316/ ONC-392 could quietly change lung cancer care - Ad-hoc-news.de
PTC Therapeutics (PTCT) moves 7.2% higher: Will this strength last? - MSN
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
BioNTech Faces Shareholder Revolt Over Spin-Off Even as It Prepares First US Cancer Filing - aktiencheck.de
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - Ad-hoc-news.de
BioNTech Stands at a Pivotal Juncture as First FDA Filing Approaches and Pipeline Data Piles Up - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
BioNTech's $1 Billion Buyback Marches Forward as Founders Exit and Cancer Trials Intensify - aktiencheck.de
BioNTech: When Pipeline Progress Meets a Market That Demands Revenue () - aktiencheck.de
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Bernstein reiterates BioNTech stock rating on pumitamig risks - Investing.com
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewswire Inc.
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
BNTXBioNTech SE ADR Stock Price and Quote - Finviz
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Grapples With Labor Strife and Analyst Skepticism as Stock Languishes () - aktiencheck.de
BioNTech’s ASCO Runway: Dual Cancer Data, a Shifting Analyst Pulse, and a Cash-Rich Pause for Growth - aktiencheck.de
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
Bernstein initiates BioNTech stock coverage citing pipeline concerns - Investing.com
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
Nobel Laureate Karikó to Speak as BioNTech Cuts 1,860 Jobs in Oncology Pivot () - aktiencheck.de
BioNTech’s €500m Cost-Cutting Drive Fails to Lift Stock as Oncology Spending Soars () - aktiencheck.de
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
3.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):